Bildkälla: Stockfoto

Xbrane Biopharma Q1 2024: Approaching an eventful second half of the year - Redeye

Redeye returns with a research update following Xbrane’s Q1 report. Sales and EBIT were lower than we had estimated, but end-customer sales grew 30%. The report prompts minor adjustments to our forecasts and valuation.

Redeye returns with a research update following Xbrane’s Q1 report. Sales and EBIT were lower than we had estimated, but end-customer sales grew 30%. The report prompts minor adjustments to our forecasts and valuation.
Börsvärldens nyhetsbrev
ANNONSER